title: Potential Use of Autologous Renal Cells from Diseased Kidneys for the Treatment of Renal Failure.
abstract: Chronic kidney disease (CKD) occurs when certain conditions cause the kidneys to gradually lose function. For patients with CKD, renal transplantation is the only treatment option that restores kidney function. In this study, we evaluated primary renal cells obtained from diseased kidneys to determine whether their normal phenotypic and functional characteristics are retained, and could be used for cell therapy. Primary renal cells isolated from both normal kidneys (NK) and diseased kidneys (CKD) showed similar phenotypic characteristics and growth kinetics. The expression levels of renal tubular cell markers, Aquaporin-1 and E-Cadherin, and podocyte-specific markers, WT-1 and Nephrin, were similar in both NK and CKD kidney derived cells. Using fluorescence- activated cell sorting (FACS), specific renal cell populations were identified and included proximal tubular cells (83.1% from NK and 80.3% from CKD kidneys); distal tubular cells (11.03% from NK and 10.9% from CKD kidneys); and podocytes (1.91% from NK and 1.78% from CKD kidneys). Ultra-structural analysis using scanning electron microscopy (SEM) revealed microvilli on the apical surface of cultured cells from NK and CKD samples. Moreover, transmission electron microscopy (TEM) analysis showed a similar organization of tight junctions, desmosomes, and other intracellular structures. The Na+ uptake characteristics of NK and CKD derived renal cells were also similar (24.4 mmol/L and 25 mmol/L, respectively) and no significant differences were observed in the protein uptake and transport characteristics of these two cell isolates. These results show that primary renal cells derived from diseased kidneys such as CKD have similar structural and functional characteristics to their counterparts from a normal healthy kidney (NK) when grown in vitro. This study suggests that cells derived from diseased kidney may be used as an autologous cell source for renal cell therapy, particularly in patients with CKD or end-stage renal disease (ESRD).
authors: Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, 27157, United States of America.
authors: Sunil K
authors: SK
authors: George
authors: Texas Tech University, Paul L. Foster School of Medicine, El Paso, Texas, 79905, United States of America.
authors: Mehran
authors: M
authors: Abolbashari
authors: Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, 27157, United States of America.
authors: John D
authors: JD
authors: Jackson
authors: RSS Urology-Mid Atlantic, Allergan Medical Affairs, P.O. Box 19534, Irvine, California, 92623, United States of America.
authors: Tamer
authors: T
authors: Aboushwareb
authors: Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, 27157, United States of America.
authors: Anthony
authors: A
authors: Atala
authors: Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, 27157, United States of America.
authors: James J
authors: JJ
authors: Yoo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000378:metabolism*; D002469:Cell Separation; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007668:Kidney / Q000166:cytology* / Q000378:metabolism / Q000648:ultrastructure; D008297:Male; D008855:Microscopy, Electron, Scanning; D008875:Middle Aged; D044968:Regenerative Medicine; D051436:Renal Insufficiency, Chronic / Q000628:therapy*; D014182:Transplantation, Autologous
chemical_list: D015415:Biomarkers